pioglitazone has been researched along with Depression, Involutional in 9 studies
Pioglitazone: A thiazolidinedione and PPAR GAMMA agonist that is used in the treatment of TYPE 2 DIABETES MELLITUS.
pioglitazone : A member of the class of thiazolidenediones that is 1,3-thiazolidine-2,4-dione substituted by a benzyl group at position 5 which in turn is substituted by a 2-(5-ethylpyridin-2-yl)ethoxy group at position 4 of the phenyl ring. It exhibits hypoglycemic activity.
Depression, Involutional: Form of depression in those MIDDLE AGE with feelings of ANXIETY.
| Excerpt | Relevance | Reference |
|---|---|---|
| "38 outpatients with bipolar disorder and current major depressive episode were randomized to pioglitazone (15-45 mg/day) or placebo." | 9.30 | Double-blind, placebo-controlled trial of pioglitazone for bipolar depression. ( Aftab, A; Brownrigg, B; Calabrese, JR; Conroy, C; D'Arcangelo, N; Ganocy, SJ; Gao, K; Goto, T; Han, H; Kemp, DE; Schinagle, M; Serrano, MB; Woods, N, 2019) |
| " We conducted the present study to compare the antidepressant efficacy of pioglitazone with another insulin-sensitizer, metformin, in obese patients with concomitant polycystic ovarian syndrome (PCOS) and major depressive disorder (MDD)." | 9.17 | Does pioglitazone improve depression through insulin-sensitization? Results of a randomized double-blind metformin-controlled trial in patients with polycystic ovarian syndrome and comorbid depression. ( Akhondzadeh, S; Ashrafi, M; Farazmand, B; Kashani, L; Modabbernia, A; Omidvar, T; Ramzanzadeh, F; Tabrizi, M; Tehraninejad, ES, 2013) |
| "38 outpatients with bipolar disorder and current major depressive episode were randomized to pioglitazone (15-45 mg/day) or placebo." | 5.30 | Double-blind, placebo-controlled trial of pioglitazone for bipolar depression. ( Aftab, A; Brownrigg, B; Calabrese, JR; Conroy, C; D'Arcangelo, N; Ganocy, SJ; Gao, K; Goto, T; Han, H; Kemp, DE; Schinagle, M; Serrano, MB; Woods, N, 2019) |
| " We conducted the present study to compare the antidepressant efficacy of pioglitazone with another insulin-sensitizer, metformin, in obese patients with concomitant polycystic ovarian syndrome (PCOS) and major depressive disorder (MDD)." | 5.17 | Does pioglitazone improve depression through insulin-sensitization? Results of a randomized double-blind metformin-controlled trial in patients with polycystic ovarian syndrome and comorbid depression. ( Akhondzadeh, S; Ashrafi, M; Farazmand, B; Kashani, L; Modabbernia, A; Omidvar, T; Ramzanzadeh, F; Tabrizi, M; Tehraninejad, ES, 2013) |
| "Mood disorders and type 2 diabetes mellitus (T2DM) are prevalent conditions that often co-occur." | 3.01 | Clinical insights into the cross-link between mood disorders and type 2 diabetes: A review of longitudinal studies and Mendelian randomisation analyses. ( Fabbri, C; Fanelli, G; Possidente, C; Serretti, A, 2023) |
| "Pioglitazone is a safe and effective adjunctive short-term treatment in patients with moderate-to-severe MDD even in the absence of metabolic syndrome and diabetes." | 2.77 | Pioglitazone adjunctive therapy for moderate-to-severe major depressive disorder: randomized double-blind placebo-controlled trial. ( Akhondzadeh, S; Ashrafi, M; Modabbernia, A; Modabbernia, MJ; Sepanjnia, K, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (11.11) | 29.6817 |
| 2010's | 7 (77.78) | 24.3611 |
| 2020's | 1 (11.11) | 2.80 |
| Authors | Studies |
|---|---|
| Possidente, C | 1 |
| Fanelli, G | 1 |
| Serretti, A | 1 |
| Fabbri, C | 1 |
| Aftab, A | 1 |
| Kemp, DE | 3 |
| Ganocy, SJ | 2 |
| Schinagle, M | 1 |
| Conroy, C | 2 |
| Brownrigg, B | 1 |
| D'Arcangelo, N | 1 |
| Goto, T | 1 |
| Woods, N | 1 |
| Serrano, MB | 1 |
| Han, H | 1 |
| Calabrese, JR | 3 |
| Gao, K | 2 |
| Köhler-Forsberg, O | 1 |
| N Lydholm, C | 1 |
| Hjorthøj, C | 1 |
| Nordentoft, M | 1 |
| Mors, O | 1 |
| Benros, ME | 1 |
| Lin, KW | 1 |
| Wroolie, TE | 1 |
| Robakis, T | 1 |
| Rasgon, NL | 1 |
| Colle, R | 1 |
| de Larminat, D | 1 |
| Rotenberg, S | 1 |
| Hozer, F | 1 |
| Hardy, P | 1 |
| Verstuyft, C | 1 |
| Fève, B | 1 |
| Corruble, E | 1 |
| Ismail-Beigi, F | 2 |
| Obral, S | 1 |
| Fein, E | 1 |
| Findling, RL | 1 |
| Sepanjnia, K | 1 |
| Modabbernia, A | 2 |
| Ashrafi, M | 2 |
| Modabbernia, MJ | 1 |
| Akhondzadeh, S | 2 |
| Kashani, L | 1 |
| Omidvar, T | 1 |
| Farazmand, B | 1 |
| Ramzanzadeh, F | 1 |
| Tehraninejad, ES | 1 |
| Tabrizi, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Double-Blind, Placebo-Controlled Trial of Pioglitazone for Bipolar Depression[NCT01717040] | Phase 4 | 37 participants (Actual) | Interventional | 2012-09-30 | Terminated (stopped due to The study ended early due to budgetary issues) | ||
| Precision Psychiatry: Anti-inflammatory Medication in Immuno-metabolic Depression[NCT05415397] | Phase 3 | 140 participants (Anticipated) | Interventional | 2022-09-28 | Recruiting | ||
| Pioglitazone as an Adjunct for Moderate to Severe Depressive Disorder[NCT01109030] | Phase 2/Phase 3 | 50 participants (Actual) | Interventional | 2010-04-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Inventory of Depressive Symptomatology-Clinician Rated (IDS-C30) is designed to assess the severity of depressive symptoms. Total scores can range from 0 to 84 with higher scores indicating a higher severity of depressive symptoms (NCT01717040)
Timeframe: Baseline and Week 8
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Pioglitazone | 31.4 |
| Placebo | 24.3 |
3 reviews available for pioglitazone and Depression, Involutional
| Article | Year |
|---|---|
Clinical insights into the cross-link between mood disorders and type 2 diabetes: A review of longitudinal studies and Mendelian randomisation analyses.
Topics: Depressive Disorder, Major; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Mood Disorders; | 2023 |
Efficacy of anti-inflammatory treatment on major depressive disorder or depressive symptoms: meta-analysis of clinical trials.
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Anti-Inflammatory Agents; Antidepressive Agents; Cyt | 2019 |
PPAR-γ Agonists for the Treatment of Major Depression: A Review.
Topics: Antidepressive Agents; Biomarkers; Blood Glucose; Depressive Disorder, Major; Fasting; Glucose Toler | 2017 |
5 trials available for pioglitazone and Depression, Involutional
| Article | Year |
|---|---|
Double-blind, placebo-controlled trial of pioglitazone for bipolar depression.
Topics: Adult; Antidepressive Agents; Antimanic Agents; Antipsychotic Agents; Bipolar Disorder; Depression; | 2019 |
Adjuvant pioglitazone for unremitted depression: Clinical correlates of treatment response.
Topics: Adjuvants, Pharmaceutic; Adult; Age Factors; Antidepressive Agents; Blood Glucose; Depressive Disord | 2015 |
Use of insulin sensitizers for the treatment of major depressive disorder: a pilot study of pioglitazone for major depression accompanied by abdominal obesity.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Double-Blind Method; Female; Humans; Hypog | 2012 |
Pioglitazone adjunctive therapy for moderate-to-severe major depressive disorder: randomized double-blind placebo-controlled trial.
Topics: Adult; Chemotherapy, Adjuvant; Citalopram; Depressive Disorder, Major; Double-Blind Method; Drug The | 2012 |
Does pioglitazone improve depression through insulin-sensitization? Results of a randomized double-blind metformin-controlled trial in patients with polycystic ovarian syndrome and comorbid depression.
Topics: Adolescent; Adult; Antidepressive Agents; Biomarkers; Depressive Disorder, Major; Double-Blind Metho | 2013 |
1 other study available for pioglitazone and Depression, Involutional
| Article | Year |
|---|---|
Antidepressant response associated with pioglitazone: support for an overlapping pathophysiology between major depression and metabolic syndrome.
Topics: Antipsychotic Agents; Depressive Disorder, Major; Drug Resistance, Multiple; Female; Humans; Hypogly | 2009 |